Zhifei Biological Submits Clinical Trial Application in China for Nasal Spray Recombinant RSV Vaccine Based on Chimpanzee Adenovirus Vector
Zhifei Biological (SHE: 300122) announced that it has submitted a clinical trial application in China...
SHE: 300122
Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax—Shifts to Demand-Driven Supply Model
Chongqing Zhifei Biological Products Co., Ltd. (SHE: 300122) announced the renewal of its long-standing supply,...
Zhifei Bio Initiates Phase I Study for DTaP-Hib Quadrivalent Vaccine – Component Combination Targets Pediatric Immunization Compliance
Chongqing Zhifei Biological Co., Ltd. (SHE: 300122) announced the initiation of a Phase I clinical...
Zhifei’s CA111 Injection Approved for Clinical Trials Targeting Weight Loss and Hypoglycemia
Chongqing Zhifei Biological Co., Ltd’s (SHE: 300122) subsidiary, Chongqing Chenan Biopharmaceutical Co., Ltd., has received...
Zhifei Biological’s Adult and Adolescent DTaP Vaccine Gains NMPA Trial Approval
Chongqing Zhifei Biological Co., Ltd. (SHE: 300122), based in China, announced that its Acellular Pertussis,...
Zhifei Biological Gains Bangladesh Approval for Dysentery Vaccine Trial
China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has received clearance from the Directorate General...
Zhifei Bio’s Trivalent Influenza Vaccine Approved for Clinical Trials in China
Zhifei Biological (SHE: 300122) announced on April 1, 2025, that its subsidiary Zhifei Longcom has...
Chongqing Zhifei Acquires 51% Stake in Chenan Bio for RMB593 Million
Chongqing Zhifei Biological Co., Ltd (SHE: 300122), the distribution partner for US giant Merck’s Gardasil...
Chongqing Zhifei Biological and GlaxoSmithKline Amend Distribution Agreement for Herpes Vaccine
China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has entered into a supplementary exclusive distribution...
Chongqing Zhifei Biological’s Influenza Vaccine Application Accepted by China’s Drug Evaluation Center
On October 24, 2024, the Center for Drug Evaluation of the National Medical Products Administration...
Chongqing Zhifei Biological’s EC Injection Receives Market Approval in Indonesia
Chongqing Zhifei Biological Co., Ltd (SHE: 300122), a leading biopharmaceutical company based in China, has...
Diversifying HPV Protection: Beijing Wantai’s Vaccine Filing Competes with Gardasil 9 in China
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd, a Chinese pharmaceutical company listed on the Shanghai...
Chongqing Zhifei Biological Reports 38.3% YOY Revenue Growth in 2023 Financial Results
Chongqing Zhifei Biological Co., Ltd (SHE: 300122), a biopharmaceutical company based in China, has released...
GSK Posts 5% YOY Growth in 2023 Financials, Vaccines Business Drives Expansion
GSK plc (NYSE: GSK), the UK pharmaceutical giant, announced its financial results for the fourth...
GSK Reports Modest 2% YOY Growth in Q3 2023 Finances, Vaccines Unit Soars 24%
UK-based pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has released its financial report for the third...
Chongqing Zhifei Partners with GSK for Shingrix Distribution in China
China-based Chongqing Zhifei Biological Co., Ltd. (SHE: 300122) has entered into a sole distribution and...
Chongqing Zhifei Biological Partners with PT Bio Farma for Global Tuberculosis Vaccine Development
China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has entered into a global cooperation memorandum...
Chongqing Zhifei Biological Launches Phase I Clinical Trial for Group B Meningococcal Vaccine
Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has announced the commencement of a Phase I...
Zhifei Renews Vaccine Supply Agreement with Merck Sharp & Dohme
China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has announced the renewal of a supply,...
Zhifei Biological Products’ BCG Vaccine Filing Accepted by China’s NMPA
China-based Chongqing Zhifei Biological Products Co., Ltd (SHE: 300122) has announced that its clinical trial...